DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Safinamide
Safinamide
Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions With
Inbrija, INN-Levodopa
207145Orig1s000
Download
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’S Disease
Eisai and Meiji Enter Into Licensing Agreement Concerning Parkinson’S Disease Drug Safinamide in Japan and Asia
MSM Chapter 1200 3/1/21
207145Orig1s000
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre- Clinical Discoveries
CLINICAL REVIEW(S) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/Istradefylline
A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Pharmacokinetics, Pharmacodynamics
Medications to Be Avoided Or Used with Caution in Parkinson's Disease
Oregon Drug Use Review / Pharmacy & Therapeutics Committee
Draft Guidance on Safinamide Mesylate
Xadago Generic Name: Safinamide Manufacturer1
Top View
Safinamide and Flecainide Protect Axons And
NCL JFC Minutes August 2017
Xadago, INN-Safinamide
Product Monograph Including Patient Medication Information
Annual Report 2006 2006 Highlights
2017 New Drug Update
Appendix B - Product Name Sorted by Applicant
(12) United States Patent (10) Patent No.: US 8,076,515 B2 Barbanti Et Al
Patil AJ and Suryawanshi MR. Review on Novel Monoamine Oxidase Inhibitors: a Clinician’S Guide
PDL)/Non-Preferred Drug List (NPDL
Medicaid List of Covered Drugs (Formulary)
Antiparkinson's Agents
Changes in Strategies in Managing Motor and Non-Motor Symptoms in Parkinson’S Disease
XADAGO (Safinamide) Tablets, for Oral Use • May Cause Or Exacerbate Dyskinesia; Consider Levodopa Dose Reduction Initial U.S
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
DRUG TREATMENTS for Parkinson's
Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs
Safinamide Improves Non-Motor Symptoms Burden In
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Australian Public Assessment Report for Safinamide
Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
A Bridging Tool Between CNS Drug Development and Therapeutic
PATIENT INFORMATION XADAGO® (ZA-Da-Go) (Safinamide) Tablets
Medicare Model Guidelines Draft V8.0 1 of 97
A Treatment Guide to Parkinson's Disease
Cost Comparison Charts
An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
PSP: Some Answers
April, 2017) 2
Safinamide Has Been Investigated in Phase III Clinical Trials As Adjunct Therapy to L-Dopa in Mid- to Late-Stage Fluctuating PD
PDL)/Non-Preferred Drug List (NPDL
Minutes of PRAC Meeting on 11-14 May 2020
Tepzz 5 58¥Zb T
AHFS Pharmacologic-Therapeutic Classification System
Medications for Insomnia
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
Parkinson's Disease with Motor Fluctuations: Safinamide
Phase 1 Cocaine Protocol Template
Sun-Protection and Drugs
Developing Uniquely Differentiated Drugs for Cns Targets
Ethanol 40 L-Glutamic Acid 39 Zonisamide 30 Picrotoxin 22
Newron Pharmaceuticals S.P.A. ("Newron") Solely for Your Information
Xadago, INN-Safinamide
XADAGO (Safinamide)
Differentiating Serotonin Syndrome and Neuroleptic Malignant Syndrome
Prescribing Information
Medications to Avoid
Computational Study on Parkinson Disease
Download Article
Minutes of PRAC Meeting on 03-06 September 2018
Supernus Prescribing Information & Patient Information
Therapeutic Drug Class
Recommended Dose of Benadryl for Allergic Reaction
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Proposed Formulary Changes Effective 4/1/2018 (Unless Otherwise Noted)